SciSparc receives FDA approval for a Phase IIb trial of a cannabinoid based treatment for Tourette Syndrome. SciSparc Ltd., a clinical-stage pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved its investigational new drug (IND), which enables the company